Triggering receptor expressed on myeloid cells 1 (TREM1) participates in the development of endometritis. This study aims at identifying the effects and interaction of TREM1 and upstream stimulatory factor 2 (USF2) in endometritis by using a model of lipopolysaccharide (LPS)-induced human endometrial epithelial cells (HEnEpCs). ELISA was performed to determine the levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF-α) after LPS stimulation. TREM1 and USF2 expression was examined with RT-qPCR and Western blot....

The dysregulated circular RNAs (circRNAs) are linked to progression and chemoresistance in colorectal cancer (CRC). However, the role of circRNA protein tyrosine kinase 2 (circPTK2) in CRC progression and chemoresistance is uncertain. The circPTK2, microRNA (miR)-136-5p, m6A ‘reader’ protein YTH domain family protein 1 (YTHDF1), β-catenin and cyclin D1 abundances were examined via quantitative reverse transcription PCR or Western blotting. The progression was investigated by cell counting kit-8 (CCK-8), colony formation, transwell and xenograft analysis....

Hyperthermia is a widely used adjunct treatment for different cancers including nasopharyngeal carcinoma (NPC). The protooncogene c-Myc is up-regulated in NPC and its expression is associated with poor prognosis. We hypothesized that c-Myc constitutes an important hyperthermia treatment target, and we investigated its contribution to hyperthermia responses in NPC. The growth of the human NPC cell lines CNE1 and CNE2 was analyzed using CCK-8 and clonogenicity assays after 43 °C hyperthermia, knockdown or overexpression of...

Additional file 2: Supplementary Fig. 2. The representative images of Fig. 4D (A), 4E (B), 4F (C), 4G (D) and 4H (E).

Additional file 11.

Additional file 7.

Additional file 8.

Additional file 9.

Additional file 3: Figure S1. (A, D, G) The heat map of 10 prognostic DEOSG expressions in the train (A), testing (D), and entire sets (G), respectively. (B, E, H) The comparison of 10 prognostic DEOSG expressions between high- and low-risk groups in the training (B), testing (E), and entire sets (H), respectively. (C, F, I) The correlations among 10 prognostic DEOSG between high- and low-risk groups in the training (C), testing (F), and entire...

Additional file 1: Supplementary Figure S1. BUSCO assembly evaluation results. C (complete): matches the BUSCO database sequence; F (fragmented): only part of the sequence can be compared with the BUSCO database; D (duplicate): multiple genes are compared with the same BUSCO; M (missing): the filtered sequence.

Additional file 1: Supplementary Figure 1.

Additional file 2. The function of tucidinostat on tumor immunity. a Functional annotation clustering of genes regulated in tumor from CT26 tumor-bearing mice on day 10 post treatment with tucidinostat (25 mg/kg, gavage, daily, n=3) or DMSO as vehicle control (DMSO, n=3). b Representative cytograms (left) or summary histograms (right) for the cell surface PD-L1 expression in CT26 cells following different doses (2.5, 5, 7.5 μM) of vorinostat, tucidinostat, and TMP-195 treatment for 24h. c...

Additional file 2: Supplementary Figure 2.

Additional file 3: Supplementary Figure 3.

Triggering receptor expressed on myeloid cells 1 (TREM1) participates in the development of endometritis. This study aims at identifying the effects and interaction of TREM1 and upstream stimulatory factor 2 (USF2) in endometritis by using a model of lipopolysaccharide (LPS)-induced human endometrial epithelial cells (HEnEpCs). ELISA was performed to determine the levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF-α) after LPS stimulation. TREM1 and USF2 expression was examined with RT-qPCR and Western blot....

Long non-coding RNAs (lncRNAs) are involved in developing hepatocellular carcinoma (HCC). The present study explored the role of lncRNA LINC01194, which is upregulated in HCC tissues and might be a vital regulator in HCC progression. Levels of LINC01194, microRNA (miR)-655-3p, and SMAD family member 5 (SMAD5) were assessed using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR). The bioactivity of Huh-7 cells was assessed using cell counting kit-8 and transwell assays and flow cytometry. Western...

The dysregulated circular RNAs (circRNAs) are linked to progression and chemoresistance in colorectal cancer (CRC). However, the role of circRNA protein tyrosine kinase 2 (circPTK2) in CRC progression and chemoresistance is uncertain. The circPTK2, microRNA (miR)-136-5p, m6A ‘reader’ protein YTH domain family protein 1 (YTHDF1), β-catenin and cyclin D1 abundances were examined via quantitative reverse transcription PCR or Western blotting. The progression was investigated by cell counting kit-8 (CCK-8), colony formation, transwell and xenograft analysis....

Additional file 3: Figure S1. (A, D, G) The heat map of 10 prognostic DEOSG expressions in the train (A), testing (D), and entire sets (G), respectively. (B, E, H) The comparison of 10 prognostic DEOSG expressions between high- and low-risk groups in the training (B), testing (E), and entire sets (H), respectively. (C, F, I) The correlations among 10 prognostic DEOSG between high- and low-risk groups in the training (C), testing (F), and entire...

Additional file 1. The effect of tucidinostat on cell proliferation, apoptosis and hepatonephric function. a Comparison of cell proliferation of 4T1, LLC, and CT26 cells treated with different doses (2.5, 5, 7.5 μM) of tucidinostat for 24 h by CCK-8 assay. b Comparison of cell apoptosis of 4T1, LLC, and CT26 cells treated with different doses of tucidinostat (2.5, 5, 7.5 μM) for 6 h by Annexin V-FITC/PI assay. c Mouse CT26 cells (5 ×...

Additional file 2. The function of tucidinostat on tumor immunity. a Functional annotation clustering of genes regulated in tumor from CT26 tumor-bearing mice on day 10 post treatment with tucidinostat (25 mg/kg, gavage, daily, n=3) or DMSO as vehicle control (DMSO, n=3). b Representative cytograms (left) or summary histograms (right) for the cell surface PD-L1 expression in CT26 cells following different doses (2.5, 5, 7.5 μM) of vorinostat, tucidinostat, and TMP-195 treatment for 24h. c...

Additional file 3. Tucidinostat plus checkpoint blockade induces improved therapeutic efficacy. a Schema of the experiment. For bioluminescence imaging (BLI) in vivo, mouse 4T1-luc (5 × 105 cells) were engrafted into the flank of BALB/c mice. When established tumors were palpable 7 days after tumor cells inoculation, mice were treated with vehicle (DMSO, n=7), tucidinostat (25 mg/kg, gavage, daily, n=7), aPD-L1 (200 μg, i.p. injection, once every 3 days, n=7), or combination (n=7). Tumors volume...

Additional file 5. Tucidinostat plus checkpoint blockade induces CCL5 secretion. a Mouse CT26 cells (5 × 105 cells) were engrafted into the flank of BALB/c mice. When established tumors were palpable 7 days after tumor cells inoculation, mice were treated with different doses (12.5, 25, 75 mg/kg, gavage, daily, n=5) of tucidinostat. The expression of CCL5 in peripheral blood serum from CT26 tumor-bearing mice on day 10 post treatment initiation. Mouse CT26 cells (5 ×...

Additional file 1: Supplementary Figure 1.

Additional file 2: Supplementary Figure 2.

Additional file 5: Supplementary Figure 5.